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Abstract: Natural products are isolated from biodiversity, that is, from plants, microorganisms, insects, and marine organisms; most of the 
biodiversity is found in about 10-12 countries located around the Equator. For a long time, people chose this option to alleviate diseases and 
the industry to discover new medicines; however, from the 70's onwards synthetic products have displaced them. Today there is a rebirth of 
natural products research and annually hundreds of new natural and synthetic bioactive molecules are reported in specialized journals. On 
the other hands, new drugs are continually required and especially there is a deficit of them to treat the so-called Neglected Diseases, which 
affect and threaten the health of billions of people in the world. These diseases paradoxically affect almost all megadiverse countries. Thus, 
the richest countries in biodiversity do not benefit from the use of natural products because research, development and production of new 
medicines are carried out in more technologically advanced countries. Why do we have so many molecules in biodiversity and journals but 
so few medicines? How could new antiparasite drugs be developed quickly and cheaply in the countries affected by Neglected Diseases? A 
feasible alternative is the Mining in Press, that is, the search of molecules in scientific literature. In this paper we analyze the reasons why 
these valuable substances have not become drugs and remain curiosities of laboratories and libraries, and the advantages of using this 
approach as a source of drugs or templates to other bioactive molecules. 
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Resumen: Los productos naturales son aislados de la biodiversidad, es decir, de plantas, microorganismos y organismos marinos; gran parte 
de la biodiversidad se encuentra en cerca de 10-12 paises localizados alrededor del Ecuador. Por mucho tiempo, la gente ha seleccionado 
esta opción para aliviar sus enfermedades y la industria para descubrir nuevas medicinas; sin embargo, desde los años 70s los productos 
sintéticos los han desplazado. Hoy hay un renacimiento de la investigación de productos naturales y anualmente cientos de nuevas 
moléculas naturales y sintéticas bioactivas son reportados en las publicaciones especializadas. De otro lado, continuamente se requieren 
nuevas drogas y especialmente hay un déficit de ellas para tratar las llamadas Enfermedades Olvidadas, que afectan y amenazan la salud de 
miles de millones de personas en el mundo. Estas enfermedades paradójicamente afectan casi todos los países megadiversos. De esta 
manera, los países más ricos en biodiversidad no se benefician del uso de productos naturales, ya que la investigación, el desarrollo y la 
producción de nuevas medicinas se lleva a cabo en países tecnológicamente avanzados. Por qué tenemos tantas moléculas en la 
biodiversidad y en las publicaciones, pero tan pocas medicinas? Cómo podrían las drogas antiparasitarias ser desarrolladas de manera mas 
rápida y barata en los países afectados por las Enfermedades Olvidadas? Una posible alternativa es la Minería de las Publicaciones, es decir, 
la búsqueda de moléculas en la literatura científica. En este artículo nosotros analizamos las razones por la cuales esas valiosas sustancias no 
han llegado a ser drogas y permanecen como curiosidades de los laboratorios y bibliotecas, y las ventajas de usar esta aproximación como 
una fuente de drogas o modelos de otras moléculas bioactivas. 
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INTRODUCTION 
Why do we need more drugs? 
The search for novel drugs is a constant human 
necessity for many reasons such as low therapeutic 
arsenal, resistance, reduced efficacy, inadequate 
treatment scheme, secondary effects, fast metabolism, 
and chemical instability, among others. Additionally, 
many diseases are classified as chronic and 
sometimes diseases require personalized 
pharmacologic attention. In some instances, we 
demand new drugs owing to the appearance of recent 
diseases like Flu and Ebola or by the rapid increase of 
others such as Alzheimer’s.  
From the industrial standpoint, innovative 
drugs are new economic opportunities. Until the 
1970s, natural products were the preferred option for 
the industry to develop new medicines, but later they 
were displaced by synthetic products and 
combinatorial chemistry, although interest in natural 
products has recently been renewed. 
On the other hand, the WHO has declared 
more than twenty diseases as Neglected Diseases; 
among them are leishmaniasis and trypanosomiasis 
(WHO, 2017). Malaria has received special attention 
in recent years and therefore is not found in this 
group. These diseases affect several billions of people 
and require more pharmacological solutions. Thus, 
the Nobel Prize for Medicine was awarded in 2015 to 
the researchers who participated in the development 
of the antimalarial artemisinin and the antiparasite 
avermectin (The Nobel Assembly at Karolinska 
Institutet, 2015). However, more efforts are required, 
since developing a medicine, whether of natural or 
synthetic origin, requires a high investment of money 
and time, as well as very expensive human teams and 
instrumental equipment. Any methodology that 
reduces these factors will be an additional 
opportunity for a drug to reach society quickly and 
cheaply. Traditionally, this has been done with 
approximations based on the organic synthesis and on 
biodiversity. Nevertheless, a lot of valuable 
information about old and new bioactive molecules 
can be found in scientific information from journals. 
In this article we discuss the role of megabiodiversity 
and the potential of scientific information in the 
discovery of new drugs, especially for Neglected 
Diseases. 
 
Where can drugs come from? 
Drugs have diverse origins, like chemical entities or 
biological information. In the first case, they can be 
found from synthetic and natural resources, while 
biological information or functional evidence 
commonly is obtained from traditional uses and 
toxicology; thus, molecules from Biodiversity must 
be considered like chemical entities and carriers of 
biological information. Additionally, it must be taken 
into account that natural substances must be 
optimized and therefore used as templates to develop 
new medicines 
 There is great concern worldwide because 
fewer drugs are being discovered (Bennani, 2011; 
Jarvis, 2016); moreover, innovation has been 
replaced by the development of the so-called “Me 
Too” medicines (Gagne & Choudhry, 2011), that is, 
chemical entities that maintain the same structural 
pharmacophore but have slight structural 
modifications to change the pharmacokinetic 
properties. 
The main sources of drugs as chemical 
entities are shown below: 
 
• From biodiversity 
• Plants 
• Marine organisms 
• Microorganisms, including 
endophytes 
• Insects 
• Tissue or microorganism culture 
elicitation and challenges  
• Metabolic Engineering 
• From Organic Synthesis 
• Combinatorial Chemistry 
• From Molecular Modeling 
• In silico 
• Virtual libraries 
• From Serendipity 
• Biological activity 
• Metabolism (biotransformation) 
• Unexpected organic synthesis  
• From Old Drugs  
• Drug Second Uses 
• From the Literature 
 
 Most of the research on natural products has 
been done on plants, and although a high percentage 
has not been studied, the interests are currently 
focusing on marine organisms (Blunt et al., 2018), 
fungi (mainly endophytes) (Hillman et al., 2017) and 
unconventional natural sources including insects 
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(Seabrooks & Hu, 2017), since they offer more 
attractive possibilities, especially to obtain new 
chemical skeletons and biological activities. 
Therefore, the richness in biodiversity is not having 
many species, but a great variation of them, since 
plant species of the same genus or tribe contain very 
similar compounds with similar pharmacologic 
actions. However, marine organisms, 
microorganisms, and synthetic molecules lack 
traditional medicine and there is not enough 
knowledge in chemotaxonomy to carry out studies to 
develop new drugs quickly. 
 It is also noteworthy that modifications on a 
partial sequence of the genome of a microorganism or 
plant can generate new natural molecules that had 
never been present in the original organism and 
elicitation in roots or cell cultures is an easier method 
to find these type of compounds. Besides, Omics 
allow valuable and accurate pharmacological targets 
to be defined  
 On the other hands, combinatory chemistry 
has been a faster way to obtain hundreds or even 
thousands of substances subsequently bioassayed 
through HTS or UHTS; although, the results have not 
been promising because synthesis is carried out on a 
solid phase, so bioavailability is usually low. 
Alternative source of new molecules is the use of 
software to design new molecular structures to build 
a virtual library. Molecular modeling allows the 
identification of a pharmacophore to establish 
relationships between the structure and activity; 
nevertheless, sometimes structures are so complex 
that is not feasible an efficient organic synthesis.  
 In addition, information from doctor’s offices 
can provide valuable information from the follow-up 
of secondary effects and the unpredicted symptoms 
after the product has been launched to the market. 
Another important component in the search for new 
drugs is serendipity (Ban, 2006; Baumeister et al., 
2013) from unexpected activities, astonishing 
reactions, and surprising metabolism or unpredicted 
symptoms.  
 These seems to suggest that there are more 
potential sources of new molecules and biodiversity 
is only one of them, like Tulip has already expressed 
it (Tulp & Bohlin, 2002): “Thus, it seems that 
biodiversity is not a unique and valuable source of 
molecules and information for new drugs, Thus, there 
are no obvious advantages of "biodiversity 
prospecting", which will, possibly, endanger fragile 
ecosystems in the search for rare species”. As 
discussed below, it does not seem to be important for 
megadiverse countries either. 
 
The role of megadiverse countries in new drug 
discovery  
Natural products have been the most abundant source 
of bioactive substances; therefore, it is assumed that 
rich countries in biodiversity are the source of many 
medicines. This would be favored because in these 
same countries there is a rich ethnomedic tradition 
and they are still used as raw drugs. However, that's 
not true. A rapid analysis of some drugs developed 
from natural products (Table No. 1) (Mark & Butler, 
2004; Kingston, 2011; Mishra & Tiwari, 2011; Dias 
et al., 2012; Cragg & Newman, 2013; Harvey et al., 
2015; Patridge et al., 2015; Campbell et al., 2017) 
shows that most of them originated mainly in the 
United States, Europe, and Asia (Japan and China), 
and only a few from megadiverse countries. In this 
last case the situation is dramatic, because they 
contribute with raw material and ethnomedic 
knowledge, but the process of development new 
medicines has not been carried out there. Moreover, 
when an active natural product with biological 
activity has been detected, the development process is 
undertaken in an industrialized country, such as 
steroids, which were first developed in Mexico, but 
the advanced research was carried out in USA. 
Another exception was the antimalarial artemisinin, 
discovered and developed in China.  
The richness in biodiversity and the poor role 
played by scientists of the megadiverse countries in 
the development of new medicines is illustrated with 
the rapamycin, whose name was taken from the 
native name of the island, Rapa Nui. This medicine 
was discovered from a microorganism in Pascua 
Island (Chile) by a Brazilian team studying natural 
products on behalf of a USA-based pharmaceutic 
(Jeffery et al., 2017) Furthermore, research into 
natural products in these countries is of the 
phytochemical type that is, more focused on the 
isolation and identification of secondary metabolites 
and with scarce support in biological activity. As 
Harvey said, “there is a widening gap between 
natural-product researchers in countries rich in 
biodiversity and drug discovery scientists immersed 
in proteomics and high-throughput screening” (Dias 
et al., 2012). 
Although the statement has been made many 
times that natural products contribute more than 70% 
of the medicines available in the market (Farnsworth, 
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1993) we must be very careful with that figure. This 
high percentage is true if anticancer drugs and 
antibiotics are considered, but in very few cases the 
intact natural product is used, like alkaloids of Vinca. 
Likewise, the structural analogues of a lead 
are considered like new drugs, as is the case of 
statins, penicillins or cephalosporins; this is the case 
of drugs called "Me Too". It is clear that these 
substances are not new medicines, since they have 
the same pharmacological target and the same 
mechanism of action. 
 
Table No. 1 
The origin and fate of some natural drugs and derivatives 
Drug or Natural Product Origen Discovery Approach 
From Europe/USA 
Aspirin-COX inhibitors Europe/USA  Traditional medicine 
Aescin Europe Traditional medicine 
Artemisinin China Screening 
Atropine Europe Traditional medicine 
Calycheamicin USA Screening 
Camptothecin China/USA Screening 
Cyclosporine Europe Screening 
Colchicine Europe Medical extrapolation 
Digoxin Europe Traditional medicine 
Daunorubicin Europe Screening 
Ergot Europe Screening 
Galanthamine Europe /USA Screening 
Galegin USA Chemical extrapolation 
Khellin Europe Traditional medicine 
Penicillin Europe Medical extrapolation 
Podophyllotoxin USA Screening 
Rifampin Europe Screening 
Statins Japan/USA Screening 
Sylibin Europa Traditional medicine 
Taxol USA Screening 
Warfarin USA Medical extrapolation 
From Megadiverse Countries 
Ecteinascidin Caribbean Sea/USA Screening 
Acyclovir Caribean Sea/USA Chemical extrapolation 
Capsaicin Bolivia, Mexico Medical extrapolation 
Epothilone Congo Screening 
Chloramphenicol Venezuela/USA Screening 
Captopril Brazil/ Europe Medical extrapolation 
Pilocarpine Brazil Medical extrapolation 
Quinine Amazonian Forest Traditional medicine 
Steroids Mexico Medical extrapolation 
Tubocurarine Amazon Forest Medical extrapolation 
Vincristine Jamaica/Puerto Rico Serendipity 
*Used as traditional medicine or site material origin vs. country of development 
 
 The discovery of new biologically active 
molecules is a long, twisted, and expensive process. 
Difficulties in developing new medicines have 
increased along with the expenses involved, which 
nearly amount to US$ $2.87 billion (DiMasi et al., 
2016). Such a high investment requires the study of 
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faster and more effective possibilities to identify a hit 
molecule and transform it into a lead and finally in a 
drug. Until a few years ago, the search for new 
medicines was based on extensive extract screening 
and the synthesis of thousands of substances; in the 
latter case, it is considered that from every 10,000 
molecules that undergo the process to develop a 
medicine, only one is released to the market (The 
Pharmaceutical Industry and Global Health, 2017). 
However, the current drug searching process is 
supported by new knowledge and technologies like 
HTS and UHTA bioassays and others. Furthermore, 
proteins are crystallized massively, and thousands of 
analogues can be designed in silico and synthesized 
efficiently in a few days by combinatorial chemistry. 
Besides, there are supplementary powerful analytical 
tools to check molecule stability and to determine the 
structure. Currently, without sacrificing a single 
mouse, it is possible to differentiate promissory 
molecules, their ADMET properties and their 
toxicological implications using specific in silico 
software. For this reason, an explanation on 
increasing costs in drug development do not have any 
support. 
 Although in the last 15 years pharmaceutical 
companies have once again shown the interest in 
biodiversity (Rouhi, 2003; Harvey et al., 2015; 
Boufridi & Quinn, 2018), several drawbacks 
consigned by the companies to natural products 
converge: 
 
• Often, biodiversity material is far away of the 
civilization and eventually the national accesses 
regulation is very slow, with many bureaucratic 
procedures which have increased with the 
Convention for Biological Diversity.  
• Collection and specimen availability is 
especially dramatic regarding marine natural 
products, which additionally have not traditional 
medicine.   
• Low material available for preclinical and 
clinical assays; the latter require kilograms of the 
bioactive molecule. Sometimes plant organs are 
forbidden to collect due to represent a great threat to 
the plant survival, such as roots or bark. In addition, 
other conditions such as temperature, season, plant 
age, and geographic affects the contents of secondary 
metabolites. 
• Low concentrations of metabolites, some of 
them unstable or soluble only in organic solvents. 
• The time-consuming nature of the 
purification processes.  
• Long time investing in structural elucidation 
• Complex structures usually with several 
chiral centers. Thus, the presence of several chiral 
centers is a great challenge to optimize a molecule. 
For this reason, many synthetic drugs available in the 
market have very little chirality compared to natural 
ones, because the purification and separation 
processes in each stage are very expensive and the 
yields are very low. 
• Finally, natural products are only chemical 
structures not drugs. The drug has to be optimized in 
its pharmacokinetic, pharmacodynamic and 
toxicological aspects to make them more effective, 
bioavailable, stable and innocuous. 
 
Why do we have so many molecules and biodiversity 
but so few antiparasite medicines? 
Latin and Central America, are the most biodiverse 
regions of the world; Brazil, Colombia, México, 
Bolivia, Peru, Ecuador, Costa Rica, and Panamá in 
addition to China, India, Australia, Madagascar, 
Congo, among others, account for more than 70% of 
Earth’s total biodiversity. Several medicines such as 
tubocurarine, chloramphenicol and quinine have been 
developed from this richness  (Mark & Butler, 2004; 
Kingston, 2011; Mishra & Tiwari, 2011; Dias et al., 
2012; Cragg & Newman, 2013; Harvey et al., 2015; 
Patridge et al., 2015; Campbell et al., 2017). 
Additionally, each country possesses countless 
knowledge in ethnomedicine owing to abundant 
practices from indigenous, afroamerican and mestizo 
people. Comprehensive ethnomedicine has been 
recorded in several classical texts on traditional 
medicine, national vademecum and natural 
pharmacopeia in many of those countries.  Despite 
their richness in fauna and flora, several endemic 
diseases known as Neglected Diseases have high 
rates of incidence in all megadiverse countries, 
except Australia. These diseases are leishmaniasis, 
trypanosomiasis, soil-transmitted helminthiases, 
schistosomiasis, cysticercosis/taeniasis, dengue, 
chikungunya, rabies, leprosy, among others.  
Like was exposed before, there is a great 
concern about the development of new drugs, and the 
same critic problem occurs when parasitic diseases 
are considered, in addition to poverty, poor sanitary 
conditions and malnutrition. Why, given such high 
biodiversity, profuse ethnomedical information and 
high levels of diseased parasite population, has been 
impossible to improve significantly the health in 
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biodiverse countries? Several research groups from 
universities and others public and private research 
centers in some megadiverse countries have carried 
out projects to search for molecules to battle some of 
the diseases previously mentioned, using data linked 
to natural products from traditional medicine. 
Regardless of these efforts, the results are far from 
being proper pharmacological solutions, although in 
some cases bioactive substances have been identified 
and tested.  
 Several facts involved in delays of drug 
development process for neglected diseases in the 
megadiverse countries can be noticed, as follows: 
 
The Position of Pharmaceutical Industry    
The pharmaceutical industry is not interested in the 
high investment of time and money required to 
produce suitable drugs that offer a very low profit in 
return. Drug development from natural products is 
also a very sensitive topic pertaining to the corporate 
image and stock price of multinational 
pharmaceutical corporations; the threat of being 
called biopirate is always present. In addition, the 
portfolio of industry is far of the neglected diseases. 
 
The Research Policies of the Biodiverse Countries 
Usually there is a lack of national policies in science 
and technology, chronic money deficiency, absence 
of modern equipment and technologies, and teams of 
multidisciplinary sciences. Neither there is a long-
term planning in science and technology. 
But in addition, the procedures to access to 
genetic and biological resources are so complicated 
and with many requirements that take too long to be 
approved. And this affects not only bioprospecting 
but also basic research and education. 
 
The Attitude of the Researchers 
There is a lack of policy continuity in the 
investigations, which are often linked to 
undergraduate and postgraduate studies; when the 
student finishes a work in natural products, that line 
is also finished. Besides, academic research is carry 
out under the same parameters of the industry, 
looking for a pure molecule with a new skeleton, 
active at low concentrations, nontoxic, druggable and 
easy to synthesize, so, publishable, or patentable. 
This is the same landscape but with few human, 
economic and technical resources.  
The publishable attitude is over to find a 
possible use or solution to a specific trouble and then 
basic science research is the only end. Due to low 
possibilities of development, basic research is a 
vicious circle; only a paper is the final result and the 
cycle repeats itself: new research in bioactive 
molecules, new publications and new graduate and 
undergraduate students.  
 
The Use/Abuse of Ethnomedical Information  
(Gertsch, 2009) 
The ethnomedical information must be evaluated 
carefully. Ethnomedical recommendations of plant 
and natural products usually include a wide collection 
of pharmacological applications. Some information 
about uses and traditional practices seem to be weak, 
controversial o uncertain; there are different common 
names and plants uses in several countries or regions 
within the same country. And to stablish a 
relationship among the morphology of a root, fruit, or 
leaf to a specific organ in the human body seems too 
irrational. Moreover, a plant is recommended, for 
example to treat diabetes, but without specifications 
about TD1 or TD2. 
 
The misuses of biological activity 
Besides, it is common to find misleading titles and 
content in scientific articles about the results in the 
lab, for example, an assay against L1210 or KB cells 
is expressed as an anticancer result when in reality is 
only a cytotoxic activity. Most recently, 
anticancerigen is similar to anticancer, or inhibition 
of renin-angiotensin enzyme is equivalent to an 
antihypertensive agent. Relief of some symptoms is 
shown as disease control i.e., diabetic complication 
treatment as anti-diabetic, and acetylcholinesterase 
inhibitors as anti-Alzheimer drugs and COX inhibitor 
is an anti-inflammatory. Moreover, the titles of 
several papers have claimed for antimalarial 
substances, but only one in vitro assay is carried out 
on the plasmodium survival, so the substances should 
be classified as anti-plasmodials. A similar situation 
is found for anti-tuberculosis vs. anti-mycobacterial, 
anti-leishmanial and leishmanicidal. Thus, a lot of 
false expectations are generated in the scientific field 
and in the society. 
Besides, a lot of the applications are about 
relieving a symptom more than curing the disease as 
presented in national natural pharmacopeias. 
 
The overestimation of bioassays and in vitro assays 
(Houghton et al., 2007) 
Frequently, in vitro tests are inadequate to explain 
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therapeutic effects. Moreover, the strain, time and 
type of incubation, plant variety, extraction 
procedure, concentration used and type of solvent or 
carrier, all influence the results. In addition, the stage 
of the organism under study might be inappropriate, 
such as the use of promastigotes instead of 
amastigotes, which are an infective stage. There is a 
possibility of false positive results, especially those 
coming from polyphenol type molecules, which seem 
to lack a defined target; also, the formation of 
artifacts or decomposition products from the original 
molecules. Occasionally, the concentration used to 
obtain good results is very high, which could induce 
problems in obtaining the raw material or undesirable 
secondary effects. 
For more accurate results the use of animal 
model diseases are recommended but they are 
expensive and require expensive animal facilities and 
bioethical committees restrict this type of bioassay. 
Frequently the therapeutic scheme is not defined; due 
to a fast response, the intraperitoneal route is the first 
election, but oral use is preferred; primary studies 
concerning bioavailability are indispensably to asses 
a good absorption and effect.  
Even phytochemical screening is used to 
detect types of natural products, with imprecise 
results and false positives and negatives. There are 
very few bioguided trials, and efforts are focused 
towards purifying molecules and assigning their 
structure and it does not correlate with their 
biological activity. Finally, it is considered that more 
than 50% of the experiments in life science research 
are not reproducible (Arnaud, 2014). 
 
Toxicity 
During the development of the bioassays, it is quite 
frequent to determine the effects of a substance or an 
extract over different cell lines, U937, Vero and 
HepG2 cells, among others. Although there is no 
consensus concerning the concentration at which 
toxicity begins, results are erroneously taken as an 
indication of general toxicity, not only like a specific 
cytotoxic (Upegui et al., 2014). Consequently, 
interest in a possible follow-up to the molecule is 
lost, although those results only indicated a specific 
effect on that particular cell and not on whole 
organism. Moreover, animals possess natural barriers 
against xenobiotics such as hepatic metabolism or 
control of intestinal absorption. This landscape is 
well different when comparing a naked cell challenge 
to a high concentration of a pure compound during 
several hours or days.  
 
Some strategies to discover bioactive molecules 
Some valuable efforts have been made to find new 
molecules to combat those neglected diseases, but 
few reach the stage of clinical assays. Most of the 
efforts are invested in basic research based on the 
search for new molecules (Wink, 2012; Pohlit et al., 
2013; Gilbeert, 2013; Goupil & McKerrow, 2014; 
Njoroge et al., 2014; Nagle et al., 2014; Zulfiqar et 
al., 2017). For example, 340 natural products and 476 
synthetic compounds were reported as 
leishmanicidal; several of them, such as canthin-6-
one, γ-fagarine, flavokavin B, quercetin, nerolidol, 
maesabalides among others, were identified as 
important compounds against Leishmania spp. 
(Hussain et al., 2014). Likewise, an array of different 
strategies to determine antiparasite bioactivity was 
considered in the lab of the author of this review. 
Specifically, against Leishmaniasis, Malaria, 
Trypanosomiasis and Tuberculosis the following 
approaches were used: Traditional Medicine (Correa 
et al., 2014), Bioguided Search Correa et al., 2006), 
Assay of Previous Bioactive Molecules from a 
Library (Cardona et al., 2006), Directed Chemical 
Transformations (Pabon et al., 2013), Synthesis of an 
Antiparasite Lead Molecule (Echeverri et al., 2004; 
Cardona et al., 2006), Structural Analysis of 
Analogues of Synthetic Molecules (Baquero et al., 
2015), Use of Coevolutive Relationships of Parasite–
Vector Insects (Genes et al., 2011), and finally, 
Assays with Animal Model Diseases (Pabon et al., 
2013; Upegui et al., 2015; Echeverri et al., 2015). 
Some of these results were as follows: 
• Sapogenins from Sapindus saponaria 
topically applied to a diseased hamster model had 
excellent antileishmanial activity in a month of 
treatment, with a positive evaluation up to two 
months after the treatment was finished. A mixture of 
these saponins with hydrazones derived from 
chromans is very active against L. panamensis in 
vivo, and the concentration, frequency of the 
application, and therapeutic scheme has been 
optimized (Echeverri et al., 2015); and now we are 
waiting to start clinical trials.  
• A semisynthetic analogue of diosgenone 
given orally caused a 38% reduction of parasitaemia 
in mice infected with Plasmodium berghei (Pabon et 
al., 2013). Given these conditions, it was necessary to 
subject the molecule to new transformation processes 
until the optimal pharmacokinetic and 
Echeverri et al.                                                                                   Because there are so many bioactive molecules and so few antiparasitic? Titulo corto) 
 
Boletin Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas/421 
 
pharmacodynamics parameters were set and minimal 
toxicity was achieved. Usually, hundreds or 
thousands of derivatives must be synthesized and 
transformed until optimal pharmacologic and 
toxicological properties are reached, like chloroquine 
or captopril. 
• The well-known xanthone -mangostin 
obtained from Garcinia mangostana was tested in 
vitro against P. falciparum and in vivo against P. 
berghei; in the latter case, there was a parasitaemia 
reduction of 80% with daily doses of 100 mg/kg 
given twice a day for seven days. Doses were 
intraperitoneal, and no toxicity symptoms were 
detected in organic and hematologic parameters 
(Upegui et al., 2015). Raw material for purification 
of kilograms or even tons is available from fruit 
endosperm, currently an industrial waste.  
• Finally, using photodynamic therapy, a 
topical formulation containing hypericin 0.5% was 
applied to hamsters to effectively control cutaneous 
leishmaniasis (Montoya et al., 2015). 
 However, there could be a faster, easier and 
cheaper way, based on the search of results in 
specialized journals, and later stages of development, 
as described below. 
 
The challenge to find new drugs. mining in press 
(mip) for bioactive molecules 
Topics related to natural products are published in a 
variety of journals, in fields such as chemistry, 
pharmacy, medicine, agriculture and food, among 
other. A quick look at the publications related to 
natural products in the last six months (Journal of  
Ethnopharmacology, Phytotherapy Research, 
Phytomedicine, Planta Medica, Journal of Natural 
Products, Fitoterapia, Natural Products 
Communication, Natural Products Research, 
Phytochemistry, Pharmaceutical Biology, Journal of 
Medicinal Chemistry, European Journal of Medicinal 
Chemistry, Bioorganic Medicinal Chemistry, Journal 
of Agriculture Food Chemistry, among others) report 
a great deal of new molecules with interesting 
biological activities, with high predominance of anti-
cancer, anti-inflammatory, cardiovascular, anti-
diabetic and recently an explosion of antioxidant 
compounds. However, there are also only a few cases 
of anti-parasites.  
A brief analysis indicates that every month, 
information on nearly 180 natural bioactive 
molecules (from approximately 15 articles/month × at 
least 2 bioactive molecules/article × 6 most known 
journals) are generated, many of which pertain to 
diseases that have a reduced pharmacological stock 
but affect hundreds of millions of people. Also, 
organic synthesis may contribute with a much greater 
quantity of molecules and many other additional 
molecules are found in libraries such as those from 
NCI and the pharmaceutical industry (Lipinski et al., 
2015).  
 Several authors have proposed literature as a 
source of information for valuable molecules 
(Banville, 2006; De Souza, 2007); this point of view 
could be a good response of poor countries to their 
own diseases. Thus, scientific literature especially 
related to natural products and synthetic bioactive 
molecules, provides tens or hundreds of molecules 
with multiple biological activities weekly or monthly. 
Usually, there are well-described assays that have as 
surplus a known structure and, occasionally, the 
preparation and biological analysis of some of their 
derivatives. Extracting this information, sorting it out 
from redundant and nonessential data, discarding 
inaccurate assays and inadequate concentrations, or 
analyzing whether the organisms were used in their 
right stages is a real mining process. Because 
searching In Press is a persistent, difficult and 
detailed search process of scientific literature to 
extract valuable information from the less useful, it 
could be termed as Mining In Press (MIP). This has 
been previously conducted to explore natural product 
sources (Hale, 2005; Banville, 2006; De Souza, 2007) 
mostly from the genomic point of view (Bachmann et 
al., 2014; Milshteyn et al., 2014). It is like the 
process known as “Repurposing Drugs” (Cragg et al., 
2014; Corsello et al., 2017) or simply “Old Drugs”, 
but in this case, the molecule is at the beginning of 
the development process.  
 MIP could be of special importance in 
countries where there are reports of neglected 
diseases because the pharmaceutical industry has 
little interest in developing medicines for those 
diseases, which cause millions of deaths a year. It 
would be easier and cheaper to develop new 
substances to combat tropical diseases from MIP than 
to start the process from the basics. Additionally, 
given that the scientific material is in the public 
domain, there is no need to either pay royalties or 
restrict the scope of their use and study due to 
existing patents. The scientific field can be 
strengthened through transformations from hits to 
leads, and bioavailability assays, metabolic studies, 
and elucidation of mechanisms of action and toxicity 
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can provide sufficient resources for good and 
innovative publications. 
 On the other hands, many preclinical research 
centers are being established worldwide in 
collaboration with academics (Cavalla, 2013; 
Vaudano, 2013; Cragg et al., 2014; Michaudel et al., 
2015; Arvidsson et al., 2016; Abou-Gharbia et al., 
2017) because drug development is more than an 
academic exercise. Some of these initiatives have 
been focused on Neglected Diseases. Likewise, 
searching strategies have been proposed, but with 
very demanding requirements of the activity criteria, 
including extremely low effective concentrations and 
Selectivity Index that are too high (Nwaka & 
Hudson, 2006).  
Although this review has been focused on 
drug development, other areas of research and 
chemical product development may benefit, such as 
dyes, flavoring, stabilizers, antioxidants, 
agrochemicals, and surfactants. This means that any 
molecule or extract that displays an adequate level of 
activity could provide the research community 
valuable and sufficient information to explore its 
possibilities. 
 In some cases, MIP offers a great number of 
benefits in the search of new drugs as shown below: 
• There are well-known and standardized 
processes of purification and synthesis. 
• It is also possible to find relevant data 
concerning chemical and physical stability, solubility, 
yielding, etc  
• There are in vitro assay models. 
• Molecules have known structures. 
• Eventually, some molecules are transformed 
to establish a preliminary structure–activity 
relationship, especially on synthetic molecules. 
• Sometimes there are animal model assays, so 
it is possible to develop approximations of their 
bioavailability. 
• Preliminary toxicity levels in some blood, 
renal, and hepatic parameters could be available. 
 
CONCLUSIONS  
The discovery and development of new medicines is 
a long and complex path whose requirements, time 
and investment have increased over the last few years 
-ironically, a time when better, faster, and more 
precise ways to isolate or design promissory 
molecules and massive bioassays are available to find 
bioactive molecules.  
Biodiversity, formerly the primary source of 
new bioactive molecules, has not been useful for the 
development of the pharmaceutical industry in 
megadiverse countries and as a solution to their 
health problems. On the other hand, searching for 
new medicines from natural sources in these 
countries is limited due to economic, social, and 
political concerns, despite being affected by the 
Neglected Disease. Furthermore, there are diverse 
sources of potentially active molecules along with 
Biodiversity for drug development. However, a high 
economic and health potential is wasted in hundreds 
of reports periodically published by scientific 
journals since these results are not explored further to 
develop new medicines. 
 In this paper, several approaches to explain 
the presence of high amounts of bioactive molecules 
but only a few drugs were presented. Similar to the 
search for bioactive molecules by in vitro, in vivo or 
in silico methods, this approach can be called Mining 
In Press, because it considers information from 
specialized journals and offers two interesting 
perspectives for industry and society.  
 For the industry, this method provides 
valuable biological information and chemical 
structures that can be transformed into other more 
active molecules, which can be eventually patented. 
For the society, this method can be an important tool 
for countries with neglected diseases in which new 
prescription drugs can be developed faster and at a 
lower cost than undergoing a complete screening. 
Despite these observations, thousands of 
molecules, or new chemical entities (NCE), new 
molecular entities (NM) or new active substances 
(NAS), as redefined by the FDA (Branch & Abranat, 
2014), are now waiting for an opportunity to be 
transformed into drugs. Meanwhile, millions of 
people are daily infected by neglected diseases, and 
thousands are dying consequently. 
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